Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1992;85:1293-1303

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shear, C. L.
Right arrow Articles by Langendorfer, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shear, C. L.
Right arrow Articles by Langendorfer, A.

Circulation, Vol 85, 1293-1303, Copyright © 1992 by American Heart Association


ARTICLES

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins

CL Shear, FA Franklin, S Stinnett, DP Hurley, RH Bradford, AN Chremos, DT Nash and A Langendorfer
Merck Sharp and Dohme Research Laboratories, West Point, PA 19422.

BACKGROUND. Lovastatin produces consistent dose-related reductions in plasma levels of low density lipoprotein (LDL) cholesterol along with variable decreases in triglycerides and increases in high density lipoprotein (HDL) cholesterol. Patient characteristics from the Expanded Clinical Evaluation of Lovastatin (EXCEL) study were examined to determine their association with the magnitude of lovastatin-induced changes in these lipids and lipoproteins. METHODS AND RESULTS. After a baseline period consisting of dietary therapy, 8,245 patients with moderate hypercholesterolemia were randomized to five groups that received 48 weeks of treatment with either placebo or daily doses of lovastatin ranging from 20 to 80 mg. By use of linear statistical models, 20 different patient characteristics were examined for modification of the dose-dependent responses observed. For LDL cholesterol, the following were associated with enhanced lowering (p less than 0.05; percent changes are placebo-corrected, adjusted mean changes from baseline for the 80-mg/day lovastatin group): full drug compliance (-41.9%) versus 80% compliance (-20.3%); an age of 65 (- 43.4%) versus 45 years (-38.1%) for women; white race (-40.9%) versus black race (-38.0%); and 4.5-kg weight gain (-42.6%) versus 4.5-kg weight loss (-37.9%). Similar relations for enhanced triglyceride lowering were found with older age and weight gain. Patients with initially low HDL cholesterol (less than 0.91 mmol/l) and high triglycerides (greater than 2.26 mmol/l) had enhanced responses for these parameters: placebo-corrected percent changes at 80 mg/day were - 27.4% for triglycerides and +12.3% for HDL cholesterol. CONCLUSIONS. Overall, patient characteristics had very little impact of clinical importance on the dose-dependent LDL cholesterol lowering found with lovastatin. In patients with initially high levels of triglycerides and low levels of HDL cholesterol, the elevation of HDL cholesterol produced by lovastatin appears to be enhanced.


This article has been cited by other articles:


Home page
CirculationHome page
M. W. Medina, F. Gao, W. Ruan, J. I. Rotter, and R. M. Krauss
Alternative Splicing of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Is Associated With Plasma Low-Density Lipoprotein Cholesterol Response to Simvastatin
Circulation, July 22, 2008; 118(4): 355 - 362.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. M. Krauss, L. M. Mangravite, J. D. Smith, M. W. Medina, D. Wang, X. Guo, M. J. Rieder, J. A. Simon, S. B. Hulley, D. Waters, et al.
Variation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated With Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin Treatment
Circulation, March 25, 2008; 117(12): 1537 - 1544.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
S. B. Clauss, K. W. Holmes, P. Hopkins, E. Stein, M. Cho, A. Tate, A. O. Johnson-Levonas, and P. O. Kwiterovich
Efficacy and Safety of Lovastatin Therapy in Adolescent Girls With Heterozygous Familial Hypercholesterolemia
Pediatrics, September 1, 2005; 116(3): 682 - 688.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
L. Campeau, D. B. Hunninghake, G. L. Knatterud, C. W. White, M. Domanski, S. A. Forman, J. S. Forrester, N. L. Geller, F. L. Gobel, J. A. Herd, et al.
Aggressive Cholesterol Lowering Delays Saphenous Vein Graft Atherosclerosis in Women, the Elderly, and Patients With Associated Risk Factors : NHLBI Post Coronary Artery Bypass Graft Clinical Trial
Circulation, June 29, 1999; 99(25): 3241 - 3247.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. A. Miettinen, K. Pyorala, A. G. Olsson, T. A. Musliner, T. J. Cook, O. Faergeman, K. Berg, T. Pedersen, J. Kjekshus, and f. t. S. S. S. Group
Cholesterol-Lowering Therapy in Women and Elderly Patients With Myocardial Infarction or Angina Pectoris : Findings From the Scandinavian Simvastatin Survival Study (4S)
Circulation, December 16, 1997; 96(12): 4211 - 4218.
[Abstract] [Full Text]